Computational chemist John Chodera uses statistical mechanics, molecular modeling, and automated biophysical experiments to help identify new potential therapeutics and investigate mechanisms of drug resistance in cancer.
Physician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including regulated intramembrane proteolysis (the Rip1 pathway); double-strand-break repair and associated DNA damage responses; and cell envelope biosynthesis.
Developmental biologist Danwei Huangfu investigates the fundamental mechanisms that govern cell identity and how they could be exploited therapeutically to manipulate cell fates in regenerative medicine.
Structural biologist Dimitar Nikolov focuses on the structural, biophysical, and biochemical characterization of the molecular mechanisms of cell-cell interactions and signal transduction in the nervous system.
Cancer geneticist Kenneth Offit focuses on gene characterization; genetic and epidemiologic studies of cancer-predisposing alleles; and the therapeutic, prognostic, and psychosocial translation of these findings.
Structural biologist Alexandros Pertsinidis uses structural molecular and structural cell biology to study novel optical imaging and spectroscopy technologies to understand the function of complex macromolecular machines inside living cells.
Computational biologist Harel Weinstein investigates the structural, dynamic, and integrative determinants of molecular and cellular mechanisms underlying physiological function and pharmacological activity.